<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37075222</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Regional spreading pattern is associated with clinical phenotype in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>4105</StartPage><EndPage>4116</EndPage><MedlinePgn>4105-4116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad129</ELocationID><Abstract><AbstractText>Increasing evidence shows that disease spreading in amyotrophic lateral sclerosis (ALS) follows a preferential pattern with more frequent involvement of contiguous regions from the site of symptom onset. The aim of our study was to assess if: (i) the burden of upper (UMN) and lower motor neuron (LMN) involvement influences directionality of disease spreading; (ii) specific patterns of disease progression are associated with motor and neuropsychological features of different ALS subtypes (classic, bulbar, primary lateral sclerosis, UMN-predominant, progressive muscular atrophy, flail arm, flail leg); and (iii) specific clinical features may help identify ALS subtypes, which remain localized to the site of onset for a prolonged time (regionally entrenching ALS). A single-centre, retrospective cohort of 913 Italian ALS patients was evaluated to assess correlations between directionality of the disease process after symptom onset and motor/neuropsychological phenotype. All patients underwent an extensive evaluation including the following clinical scales: Penn Upper Motor Neuron Score (PUMNS), MRC Scale for Muscle Strength and the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). The most frequent initial spreading pattern was that towards adjacent horizontal regions (77.3%), which occurred preferentially in patients with lower MRC scores (P = 0.038), while vertical diffusion (21.1%) was associated with higher PUMNS (P &lt; 0.001) and with reduced survival (P &lt; 0.001). Non-contiguous disease spreading was associated with more severe UMN impairment (P = 0.003), while contiguous disease pattern with lower MRC scores. Furthermore, non-contiguous disease spreading was associated with more severe cognitive impairment in both executive and visuospatial ECAS domains. Individuals with regionally entrenching ALS were more frequently female (45.6% versus 36.9%; P = 0.028) and had higher frequencies of symmetric disease onset (40.3% versus 19.7%; P &lt; 0.001) and bulbar phenotype (38.5% versus 16.4%; P &lt; 0.001). Our study suggests that motor phenotypes characterized by a predominant UMN involvement are associated with a vertical pattern of disease progression reflecting ipsilateral spreading within the motor cortex, while those with predominant LMN involvement display more frequently a horizontal spreading from one side of the spinal cord to the other. These observations raise the hypothesis that one of the mechanisms underlying disease spreading in ALS pathology is represented by diffusion of toxic factors in the neuron microenvironment. Finally, it is possible that in our cohort, regionally entrenching ALS forms are mainly observed in patients with atypical bulbar phenotypes, characterized by a slowly progressive course and relatively benign prognosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maranzano</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3642-9584</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3977-6995</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0689-2989</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4398-2051</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doretti</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1015-7365</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetti</LastName><ForeName>Ruggero</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Residency Program, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagliardi</LastName><ForeName>Delia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneri</LastName><ForeName>Megi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maderna</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5052-8618</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4027-958X</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7698-3854</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, Milan, 20122, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword><Keyword MajorTopicYN="N">motor neuron disease (MND)</Keyword><Keyword MajorTopicYN="N">motor phenotype</Keyword><Keyword MajorTopicYN="N">site of onset</Keyword><Keyword MajorTopicYN="N">somatotopic organization of motor system</Keyword></KeywordList><CoiStatement>A.M., F.V., E.C., B.P., A.D., R.B., D.G. M.M., L.M., S.M., S.C. and C.M. report no disclosure. V.S. received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, LiquidWeb Srl and Novartis Pharma AG. He receives or has received research support from the Italian Ministry of Health, AriSLA, and E-Rare Joint Translational Call. He is on the Editorial Board of <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i>, <i>European Neurology</i>, <i>American Journal of Neurodegenerative Disease</i> and <i>Frontiers in Neurology</i>. N.T. received compensation for consulting services from Amylyx Pharmaceutical and Zambon Biotech SA. He received research funding from the Italian Ministry of Health and AriSLA. He is associate editor of <i>Frontiers in Aging Neuroscience</i>.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37075222</ArticleId><ArticleId IdType="pmc">PMC10545526</ArticleId><ArticleId IdType="doi">10.1093/brain/awad129</ArticleId><ArticleId IdType="pii">7131295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, et al. . The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Tredici KD, Braak H, Ludolph A. The multisystem degeneration amyotrophic lateral sclerosis&#x2014;Neuropathological staging and clinical translation. Arch Ital Biol. 2017;155:118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">29405032</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med. 2017;7:a024117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS Motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowers WR. A manual of diseases of the nervous system. 1st ed. J. &amp; A. Churchill; 1886-1888.</Citation></Reference><Reference><Citation>Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: Rostral-caudal distribution of lower motor neuron loss postmortem. Neurology. 2007;68:1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekiguchi T, Kanouchi T, Shibuya K, et al. . Spreading of amyotrophic lateral sclerosis lesions&#x2013;multifocal hits and local propagation? J Neurol Neurosurg Psychiatry. 2014;85:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">24027298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamphlett R, Kril J, Hng TM. Motor neuron disease: A primary disorder of corticomotoneurons? Muscle Nerve. 1995;18:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou SM, Norris FH. Issues &amp; opinions: Amyotrophic lateral sclerosis: Lower motor neuron disease spreading to upper motor neurons. Muscle Nerve. 1993;16:864&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">8332139</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. . Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis: ALS stages. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Attarian S, Vedel JP, Pouget J, Schmied A. Progression of cortical and spinal dysfunctions over time in amyotrophic lateral sclerosis: Progressive dysfunction in ALS. Muscle Nerve. 2008;37:364&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18080998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan JA, Hudson AJ. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain. 1991;114:843&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">2043953</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohme K, Maravic MV, Gasser T, Borasio GD. A case of amyotrophic lateral sclerosis with a very slow progression over 44 years. Neuromuscul Disord. 2001;11:414&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">11369195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Chen L, Tian J, Fan D. Differentiating slowly progressive subtype of lower limb onset ALS from typical ALS Depends on the time of disease progression and phenotype. Front Neurol. 2022;13:872500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9158116</ArticleId><ArticleId IdType="pubmed">35665030</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group . Phenotypic heterogeneity of amyotrophic lateral sclerosis: A population based study. J Neurol Neurosurg Psychiatry. 2011;82:740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve. 2020;61:508&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine MS, Ballard E, O&#x2019;Rourke P, Kiernan MC, Mccombe PA, Henderson RD. Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3&#x2013;4):184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">26700804</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranzano A, Poletti B, Solca F, et al. . Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis. Euro J Neurol. 2022;29:1402&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">34989063</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, et al. . The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7&#x2013;8):489&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis&#x2014;Frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3&#x2013;4):153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberici A, Geroldi C, Cotelli M, et al. . The frontal behavioural inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer&#x2019;s disease. Neurol Sci. 2007;28:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17464470</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata NK, Kwan JY, Danielian LE, et al. . White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain. 2011;134:2642&#x2013;2655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170531</ArticleId><ArticleId IdType="pubmed">21798965</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Mills R. Progression in primary lateral sclerosis: A prospective analysis. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):339&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434688</ArticleId><ArticleId IdType="pubmed">19922121</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn L, Stephen M, Floeter MK. Disease spread through contiguity and axonal tracts in primary lateral sclerosis: Short reports. Muscle Nerve. 2014;49:439&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545964</ArticleId><ArticleId IdType="pubmed">24464677</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromicho M, Figueiral M, Uysal H, et al. . Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Ann Clin Transl Neurol. 2020;7:1181&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359118</ArticleId><ArticleId IdType="pubmed">32558369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Stack J. The lower motor neuron homunculus. Brain. 2022;145:3727&#x2013;3729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9679163</ArticleId><ArticleId IdType="pubmed">36029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Turner MR, Lemon R. Tools and talk: An evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis: Issues &amp; opinions: Evolutionary aspects of ALS. Muscle Nerve. 2014;49:469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24273101</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010;33:409&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Catani M. A little man of some importance. Brain. 2017;140:3055&#x2013;3061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841206</ArticleId><ArticleId IdType="pubmed">29088352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemon RN. Descending pathways in motor control. Annu Rev Neurosci. 2008;31:195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo G, Marliani A, Battaglia S, et al. . Diagnostic and prognostic value of conventional brain MRI in the clinical work-up of patients with amyotrophic lateral sclerosis. JCM. 2020;9:2538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7463468</ArticleId><ArticleId IdType="pubmed">32781557</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ. The cognitive profile of ALS: A systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry. 2016;87:611&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HG, Chen L, Tang L, Zhang N, Fan DS. Clinical features of isolated bulbar palsy of amyotrophic lateral sclerosis in Chinese population. Chin Med J. 2017;130:1768&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547826</ArticleId><ArticleId IdType="pubmed">28748847</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Vucic S, Kiernan MC. Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">21702735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>